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Background: Despite the recent progress in screening and therapy, a majority of prostate cancer cases eventually attain
hormone refractory and chemo-resistant attributes. Conventional chemotherapeutic strategies are effective at very high
doses for only palliative management of these prostate cancers. Therefore chemo-sensitization of prostate cancer cells
could be a promising strategy for increasing efficacy of the conventional chemotherapeutic agents in prostate
cancer patients. Recent studies have indicated that the chemo-preventive natural agents restore the pro-apoptotic
protein expression and induce endoplasmic reticulum stress (ER stress) leading to the inhibition of cellular proliferation
and activation of the mitochondrial apoptosis in prostate cancer cells. Therefore reprogramming ER stress-mitochondrial
dependent apoptosis could be a potential approach for management of hormone refractory chemoresistant prostate
cancers. We aimed to study the effects of the natural naphthoquinone Shikonin in human prostate cancer cells.
Results: The results indicated that Shikonin induces apoptosis in prostate cancer cells through the dual induction of the
endoplasmic reticulum stress and mitochondrial dysfunction. Shikonin induced ROS generation and activated ER stress
and calpain activity. Moreover, addition of antioxidants attenuated these effects. Shikonin also induced the mitochondrial
apoptotic pathway mediated through the enhanced expression of the pro-apoptotic Bax and inhibition of Bcl-2,
disruption of the mitochondrial membrane potential (MMP) followed by the activation of caspase-9, caspase-3,
and PARP cleavage.
Conclusion: The results suggest that shikonin could be useful in the therapeutic management of hormone refractory
prostate cancers due to its modulation of the pro-apoptotic ER stress and mitochondrial apoptotic pathways.
Keywords: Shikonin, Prostate cancer, Endoplasmic reticulum stress, Calpain pathway, ROS, Mitochondrial dysfunctionBackground
Prostate cancer is one of the leading causes of urino-genital
cancer related deaths in men [1]. Despite the initial
response to androgen deprivation, the disease gradually
progresses to a hormone-refractory state due to cumulative
genetic alterations resulting in progressive clinical deterior-
ation [2]. Despite the recent advances in diagnostic
methods and improvement in treatment strategies mostly* Correspondence: dpm@cdri.res.in
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unless otherwise stated.using androgen pathway inhibitors, the prognosis of hor-
mone refractory prostate cancers in advanced stages
remains largely unsatisfactory [3,4]. Therefore there is a
urgent need for expedited development of effective thera-
peutic agents against hormone refractory prostate cancers.
Aberrant accumulation of unfolded/misfolded proteins
and lipids or sudden changes of the endoplasmic
reticulum Ca2+ homeostasis leads to a cellular adaptive
response known as endoplasmic reticulum stress (ER
stress). However, excessive ER stress is believed to be in-
tricately associated with oxidative stress and mitochon-
drial dysfunction, resulting in apoptotic cell death [5-7].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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apoptotic ER stress could be a potential strategy for
chemo-sensitization of hormone refractory prostate
cancer cells [8-10].
Shikonin, a natural naphthaquinone compound from the
herb Lithospermum erythrorhizon is known to act on a var-
iety of molecular targets associated with carcinogenesis and
shows similar potency towards drug sensitive and drug-
resistant cancer cell lines [11-17]. Furthermore, Shikonin is
used as a food additive in many countries and has favorable
toxicity, pharmacokinetic and pharmacodynamic profiles
[15,16,18]. However its effects on pro-apoptotic-ER stress
in hormone refractory prostate cancer cells is unknown.
Therefore in the present study, we examined the
effects of Shikonin on DU-145 and PC-3 prostate can-
cer cells and investigated the molecular mechanisms
involved in the process.Methods
Materials and reagents
Hormone refractory prostate cancer cell lines DU-145,
PC-3 and PrEC, a normal prostate cell type were pur-
chase from ATCC (ATCC; Manassas, VA, USA) and
Lonza (Walkersville, MD USA) respectively. The details
of the cell lines used in this study are summarized in the
(Additional file 1: Table S1). RPMI-1640 media and fetal
bovine serum (FBS) were purchased from Gibco Life
Technologies (Life Technologies, Inc., Rockville, MD,
U.S.A.). Shikonin and Salubrinal (ER stress inhibitor) were
purchased from Calbiochem (San Diego, CA, U.S.A.).
4′,6-diamidino-2-phenylindole (DAPI), and 5,5′,6,6′-tetra-
chloro-1,1′,3,3′-tetraethyl- benzimidazolylcarbocyanine iod-
ide (JC-1) were obtained from Invitrogen (Carlsbad,
CA, U.S.A.). Trypsin, streptomycin, penicillin, N-acetyl
cysteine (NAC), glutathione (GSH) and Catalase were ob-
tained from Sigma Chemical Co. The antibodies used in
this study were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, U.S.A.). Caspase colorimetric assay
kits were purchased from Millipore (Billerica, CA, USA).
Rest of the chemicals used in the study were from Sigma
(St. Louis, MO, U.S.A.) unless otherwise stated.Cell culture and treatment
DU-145, PC-3 and PrEC cells were grown in RPMI 1640
medium (Life Technologies, Inc., Rockville, MD) with
10% heat-inactivated fetal bovine serum (FBS; Life Tech-
nologies, Inc.) or DMEM (Life Technologies, Inc.) sup-
plemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, UT, USA) at 37°C with 5% CO2 incubator. Stock of
Shikonin was prepared in DMSO and stored in −20°C, cells
were treated with different concentration and time periods
with Shikonin for different experiments.Cell viability assay
Cell viability was measured using the CCK-8 assay kit in
(PC-3 and DU-145) hormone refractory prostate cancer
cells and PrEC cells as per the manufacturer’s instruc-
tions. Cells were treated with Shikonin for various time
points, at the end of treatment, the absorbance was
read using a Fluostar Omega Spectrofluorimeter (BMG
Technologies, Offenburg, Germany). All the experi-
ments were repeated at least thrice.Cell proliferation assay
Cellular proliferation was measured by measurement of
bromodeoxyuridine (BrdU) incorporation into DNA
using a nonradioactive colorimetric assay using ELISA
(Roche Applied Science, Indianapolis, IN) as per the
manufacturer’s instructions. All the experiments were
repeated at least thrice.Flowcytometry
Assessment of DNA fragmentation was done using the
TUNEL assay according to a previously standardized
procedure [19]. Briefly, cells were harvested and fixed
in freshly prepared 4% para-formaldehyde in PBS for
30 min at 4°C and then in 70% ethanol for 1 h at 4°C.
Subsequently the fixed cells were permeabilized using
0.2% Triton X-100 in 0.1% sodium citrate. The DNA
labeling mixture containing terminal deoxynucleotidyl
transferase was then added. Cells were incubated overnight
at room temperature and washed twice with PBS. Controls
were resuspended in the TUNEL reaction mixture contain-
ing fluorescent dUTP without terminal deoxynucleotidyl
transferase. Finally the analysis was carried out in a BD LSR
flow cytometer (Becton–Dickinson, San José, CA).Measurement of reactive oxygen species
For measurement of reactive oxygen species, the cell
permeant probe CM-H2DCFDA was used. The dye was
dissolved in dimethyl sulfoxide, and dilutions were made
in culture medium. Cells were seeded overnight in 6-well
plates with various treatments. At the end of treatments
the cells were incubated with 20 μM of the fluorescent
probe 2′,7′-dichlorofluorescein diacetate (DCF-DA) for
30 min. At the end of the incubation period adherent
cells were trypsinized and collected. After washing twice
with phosphate-buffered saline (PBS, pH 7.4) the fluor-
escence was monitored at an excitation wavelength of
488 nm and an emission wavelength of 530 nm in a
Fluostar Omega Spectrofluorimeter (BMG Technologies,
Offenburg, Germany) over a period of time. For each
experiment, fluorometric measurements were performed
in triplicate and expressed as fluorescence intensity units.
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The intracellular Ca2+ levels in DU-145 and PC-3 cells
were determined using flourimetry with the Fluo-4 AM
dye (Invitrogen Carlsbad, CA, U.S.A.). Cells were cul-
tured in specialized 96-well plates and loaded with 5 μM
of Fluo-4 AM fluorescent dye for 30 min at 25°C. Exper-
iments were performed in Hanks’ Balanced Salt Solution
(HBSS) solution containing (mM); NaCl, 142; KCl, 5.6;
MgCl2, 1; CaCl2, 2; Na2HPO4, 0.34; KH2PO4,0.44; HEPES,
10; glucose, 5.6; buffered to pH 7.4 with NaOH. The
Ca2+ −free HBSS had the same constituents as HBSS solu-
tion, but with no CaCl2 and with EGTA 1 mM added to
eliminate any possible calcium contamination. Fluorescence
measurements were performed at an excitation of 488 nm
and an emission of 522 nm Fluostar Omega Spectrofluo-
rimeter (BMG Technologies, Offenburg, Germany). All the
experiments were repeated at least thrice.
Calpain activity assays
DU-145 and PC-3 cells were cultured on 24-well plates
and pretreated with BAPTA, a Ca2+ chelator or calpeptin
and an inhibitor of calpain for 1 h. Then, cells were
loaded with 40 M Suc- Leu-Leu-Val-Tyr-AMC calpain
protease substrate (Biomol, USA,) and treated with
shikonin to the indicated time at 37°C in a humidified
5% CO2 incubator. Proteolysis of the fluorescent probe
was monitored by a Fluostar Omega Spectrofluorimeter
(BMG Technologies, Offenburg, Germany) with filter
settings of 360 nm for excitation and 460 nm for emis-
sion. All the experiments were repeated at least thrice.
Western blotting analysis
The protein content of the control and treated cell extracts
was measured by the Bradford assay. The western blotting
was done as per a previously standardized protocol [19].
Briefly, each of the samples 50 μg of protein were electro-
phoresed on 10–12% SDS–PAGE gels and transferred to
nitrocellulose membranes. Membranes were blocked,
incubated with primary antibodies at the appropriate
concentration, and subsequently incubated with horse-
radish peroxidase-conjugated goat anti-rabbit IgG or
goat anti-mouse IgG (1:5000 dilution). Labeled bands
were detected by Immobilion western chemiluminescence
horseradish peroxidase kit and images were captured.
Densitometric analysis for determination of relative protein
expression was done using a Doc image system (Bio-Rad,
Laboratory, UK) with β-actin as loading control.
Measurement of mitochondrial membrane potential
The integrity of mitochondrial membrane potential
(Δψ) was measured by JC-1 (5, 5′, 6, 6′-tetrachloro-1,
1′, 3, 3′-tetraethyl-benzimidazolylcarbocyanine iodide;
T-3168; Molecular Probes, Eugene, OR), a cationic dye
that exhibits potential-dependent accumulation inmitochondria, indicated by a fluorescence emission
shift from green (527 nm) to red (590 nm). With nor-
mal mitochondrial function, Δψ is high and red fluor-
escence is predominant. After injury to mitochondria,
Δψ is reduced and an increase in green fluorescence is
observed. At the end of the treatments, cells were
washed and incubated with JC-1 dye at the concentration
of 10 μg/ml in media for 15 min at 37°C. The presence of
depolarized mitochondria was identified by fluorimetry.
The ratio of the reading at 590 nm to the reading at 530
nm (590:530 ratio) was considered as the relative (Δψ)
value. All the experiments were repeated thrice.
Caspase activity assay
To measure caspase-9 and caspase-3 activities, cell lysates
were prepared from cells treated with Shikonin for 24 h or
with various treatments and analyzed using the caspase-9
and caspase- 3 colorimetric activity assay kits as per the
manufacturer’s instructions. All the experiments were
repeated thrice.
Statistical analysis
The data shown are a summary of the results from at
least three independent experiments and are presented
as the means ± standard error (SEM.). A statistical
evaluation of the results was performed with one-way
analysis of variance (ANOVA). The results were consid-
ered significant at a value of p < 0.05.
Results
Shikonin inhibits proliferation of prostate cancer cells
without affecting normal prostate epithelial cells
Hormone refractory prostate cancer cells (DU-145 and
PC-3) were treated with various doses of Shikonin (0.5,
1, 2.5, 5 and 10 μM) for 24 h. Cell viability was deter-
mined using the CCK-8 assay kit. The results indicated
that the IC50 dose of Shikonin was ~ 5.0 μM in DU-145
cells and ~4.5 μM in PC-3 respectively. Consistent with
earlier studies shikonin inhibited viability of a variety of
non-prostate cancer cell types while sparing the normal
cell types (Additional file 2: Figure S1). Furthermore,
Shikonin inhibited proliferation of prostate cancer cells in a
dose dependent manner (Additional file 2: Figure S2).
While no significant (p > 0.05) effect on cell viability was
observed in normal prostate epithelia cells (PrEc). Since a
significant (~42%, p < 0.05) decrease in the cell viability was
observed in both these cell lines treated with 2.5 μM of
dose of Shikonin (Figure 1A), we selected this dose for the
mechanistic experiments of the study. DNA fragmentation
a characteristic of the apoptotic cells was quantified by the
flowcytometry based TUNEL assay in Shikonin treated
cells. The results depicted a significant (p < 0.05) in-
crease in the TUNEL positive cells with Shikonin treat-
ment (Figure 1B). Cleavage of PARP, a highly conserved
Figure 1 Shikonin treatment selectively induces apoptosis in prostate cancer cells. (A) Shikonin treatment inhibits prostate cancer cell
viability without affecting normal prostate epithelial cells. DU-145, PC-3 and PrEC cells were treated with various doses (0.5, 1, 2.5, 5 and 10 μM) of
Shikonin for 24 h and CCK-8 assay was used for the measurement of cell viability. (B) Shikonin treatment induces DNA fragmentation in prostate
cancer cells. Cells were treated with various doses (0.5,1,2.5, 5 and 10 μM) of Shikonin for 24 h and TUNEL assay was done using flow cytometry
and the % TUNEL positive cells were measured. (C) Shikonin treatment induces PARP activation. Cells were treated with 2.5 μM of Shikonin for 24
h and the cell lysates were analyzed by western blotting for the detection of cleaved PARP, a marker for PARP activation. (D) Shikonin treatment
induces caspase-3 activation. Cells were treated with various doses of Shikonin (0.5, 1, 2.5, 5 and 10 μM) for 48 h and measurement of caspase-3
activity was done using the CASPASE-3 Colorimetric Activity Assay kit. Data is expressed in means ± SEM and represents the results of three independent
experiments (p < 0.05).
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cated in the apoptotic response of cells. Immunoblotting
experiments clearly showed that Shikonin treatment in-
duced PARP activation characterized by the cleaved PARP
fragment in DU-145 and PC-3 cells, interestingly we did
not observed any PARP clevage in PrEcs (Figure 1C). Acti-
vation of caspase-3 like proteases play a crucial role in
apoptotic cell death, therefore we next determined the
caspase-3 activities in Shikonin treated and DU-145 and
PC-3 cells. A ~5.8-fold increase in the caspase-3 activ-
ities over control cells was observed in these cell lines
(Figure 1D; p < 0.05). Collectively, these results indicated
that shikonin inhibited proliferation of the prostate cancer
cells through induction of apoptotic cell death.
Shikonin treatment induces ROS generation, intracellular
calcium and ROS-dependent mitochondrial apoptosis in
prostate cancer cells
There is a close relationship between ROS and Ca2+ in
apoptotic signal transduction pathways [20]. Shikonin isknown to influence intracellular Ca2+ [20] and ROS gen-
eration in different cancer cells types [21-23] but similar
modulation of intracellular Ca2+ in hormonal refractory
prostate cancer cells has not been elucidated. Our re-
sults indicated that Shikonin treatment induces time
dependent ROS generation, which could be rescued with
pretreatment of antioxidants (NAC, GSH and Catalase)
in both DU-145 (Figure 2A) and PC-3 (Figure 2B) cells.
ROS mediated free intracellular Ca2+ is known to be in-
volved in ER stress induced apoptotic signaling [24].
Therefore we further investigated for these changes, in
DU-145 and PC-3 cell, treated with Shikonin. We
observed a marked increase in the intracellular Ca2+
levels (Figure 2C) and Calcium-Activated Neutral Pro-
tease (Calpain) activity as early as 60 min (Figure 2D)
in shikonin treated DU-145 and PC-3 cells. Pretreat-
ment with ROS inhibitors (NAC, GSH and Catalase)
attenuated ROS-induced intracellular Ca2+ levels in
DU-145 (Figure 2E) and PC-3 cells (Figure 2F). Exces-
sive generation of ROS renders the cells oxidatively
Figure 2 Shikonin treatment induces ROS generation, increase in Intracellular Calcium in prostate cancer cells. (A-B) Shikonin induces ROS
generation in prostate cancer cells. DU-145 (A) and PC-3 (B) cells were seeded in 6-well plates overnight in the presence or absence of Shikonin,
and incubated with DCF-DA 50 μM for 30 min, washed three time with ice cold PBS. Generation of ROS was measured using flourimetry as per
standard protocol. (C) Shikonin induces increase in intracellular Calcium in Shikonin treated prostate cancer cells. The level of intracellular calcium
in DU-145 and PC-3 cells were determined using flourimetry technique in cells using the Fluo-4AM (50 μM/ml) dye in Shikonin treated prostate
cancer cells as described in material and methods. (D) Shikonin treatment induces calpain activity in prostate cancer cells. Shikonin treated
prostate cancer cells were analyzed for calpain activity as described in as described in material and methods. (E-F) Antioxidant pretreatment
reverses shikonin induced increase in the intracellular calcium. DU-145 and PC-3 cells were pretreated with NAC (20 μM), GSH (10 mM) or
Catalase (20 nM) for 2 hours and the ROS inhibitor rescued intracellular calcium release was measured as described in the Methods section.
Values are represented as Mean ± SEM, from three independent experiments.
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mitochondrial dysfunction and apoptotic cell death
[25]. Shikonin treatment induced significant loss of
mitochondrial membrane potential (Figure 1A) and
modulated pro-anti-apoptotic mitochondrial proteins
expression (Figure 1B) in these cells. Our western blot
analysis showed that shikonin activated expression of
the upstream proteins Bax, cytochrome c as well as
downstream caspases 7 and AIF in both prostate can-
cer cell types (Figure 1B). Moreover, pre-incubation
with ROS inhibitors (NAC, GSH and Catalase) attenu-
ated these effect in both cell types (Figure 1C).Collectively these results indicated that Shikonin treat-
ment induces ROS generation, increases in intracellular
calcium levels and ROS-dependent mitochondrial apoptosis
in prostate cancer cells.
Shikonin treatment induces oxidative stress mediated
induction of ER stress related protein expression
As the previous results suggested that Shikonin treatment
induced intracellular Ca2,+ calpain activation and gener-
ation of ROS in prostate cancer cells (Figures 2 and 3), we
therefore explored whether Shikonin can activate ROS
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Figure 3 Shikonin induces ROS dependent mitochondrial apoptosis in prostate cancer cells. (A) Shikonin modulated mitochondrial
membrane potential in DU-145 and PC-3 cells. The integrity of mitochondrial membrane potential (Δψ) was measured by JC-1 mitochondrial dye.
Briefly DU-145 and PC-3 cells were treated with 2.5 μM for 0–24 h. Ratio of 590/530 nm was measured by flow cytometry as described in material
and methods. Data is expressed in means ± SEM and represent the results of three independent experiments (p < 0.05). (B) Shikonin treatment
alters expression of mitochondrial proteins in DU-145 and PC-3 cells. Cells were treated with Shikonin for 0-24 h, expression of indicated mitochondrial
proteins were performed as described in Methods. Experiments were repeated minimum two-four times. (C) Shikonin induced ROS
dependent mitochondrial apoptosis in DU-145 and PC-3. Cells were pretreatment with the antioxidants NAC (20 μM) GSH (10 mM) and
Catalase (20 nM) and western bolting experiments were performed as described in Methods section. Data is represents the results of
three independent experiments.
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ROS generation, intracellular Ca2+ and activation of
ER stress leads to mitochondrial apoptosis in cancer
cells [26-28]. Therefore, we further examined ER stress
associated proteins in these cell lines. First, the phos-
phorylation patterns of PERK and eIF2α were assessed,
since PERK, an ER-resident transmembrane kinase, is
known to auto phosphorylate its cytoplasmic kinasedomain in response to accumulated unfolded proteins
in the ER lumen and activated PERK is subsequently
capable of phosphorylating several cytosolic proteins
including eIF2α [29-32]. Western blot analysis revealed
that treatment of cells with Shikonin (2.5 μM) led to
an increase in the phosphorylation of PERK up to 24 h
and eIF2α for up to 9 h of treatment (Figure 4A). The
expression of GRP78/Bip, which serves as a gatekeeper
Figure 4 Shikonin induces reactive oxygen species mediated ER Stress. (A) Shikonin treatment induces ER stress associated protein expression.
Western blot experiments in prostate cancer cells treated with 2.5 μM of Shikonin increased the phosphorylation of PERK, and its substrate eIF2α,
increased expression of GRP78/Bip and CHOP/GADD135 in a time-dependent manner. (B) DU-145 and PC-3 cells were pretreated with either
NAC (20 μM), GSH (10 mM) or Catalase (20 nM) for 2 h and treated with Shikonin (2.5 μM) for 24 h and the indicated protein levels were measured
using Western blotting. Representative data of three independent experiments are presented.
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examined. The results indicated that treatment with
Shikonin significantly increased the expression of GRP78/
Bip and CHOP/GADD135 and led to a decrease in the
expression of procaspase-3 were ROS dependent man-
ner (Figure 4B). These results collectively suggested
that the intracellular ROS were directly involved in the
regulation of ER stress induced by shikonin in prostate
cancer cells.
Shikonin regulates endoplasmic reticulum stress through
modulation of intracellular calcium in prostate cancer
cells
We next assessed the expression of ER stress proteins as
many studies have implicated the interplay between, ROS,
mitochondria, intracellular Ca2+ and calpain activity deter-
mines ER stress and cell survival in cancer cells [32-34].
The results indicated that pretreatment with the Ca2+
chelator, BAPTA or the ER stress inhibitor Salubrinal
inhibited the shikonin induced expression of p-pERK,
p-pelF2α, CHOP/GADD153 and caspase 4 activity
(Figure 5A). Furthermore, our cell proliferation data in
presence of BAPTA (a Ca2+ chelator) or calpeptin (a calpain
inhibitor) for 1h, also confirmed that Shikonin mediatedcell death involves calcium signaling in prostate cancer
DU-145 and PC-3 cells (Figure 5B).
Inhibition of ER stress response by salubrinal attenuated
shikonin induced effects
To investigate the mitochondrial apoptotic events in-
volved in shikonin-induced apoptosis, the levels of the
antiapoptotic protein Bcl-2 and the pro-apoptotic pro-
tein Bax were analyzed. Western blot analysis showed
that the treatment of DU-145 and PC-3 cells with Shikonin
resulted in a marked reduction in the expression of Bcl-2
and increased the level of Bax and cleaved PARP when
compared with untreated cells (Figure 6A). These results
suggested that shikonin alters the levels of pro- and anti-
apoptotic proteins of the Bcl-2 family in a manner that con-
tributes to the shikonin-induced apoptosis. Salubrinal is an
inhibitor of the serine/threonine phosphatase PP1 and
inhibits eIF2α dephosphorylation that in turn blocks ER
stress-induced cell death [35,36]. The inhibition of ER stress
in DU-145 and PC-3 cells by salubrinal led to the increased
expression of Bcl-2 and decreased the levels of Bax and
cleaved PARP, in contrast to cells treated with Shikonin
alone, indicating that Shikonin treatment -induced the
mitochondrial apoptotic pathway (Figure 6A). Similarly,
Figure 5 Induction of ER stress is critical in Shikonin induced effects in DU-145 and PC-3 prostate cancer cells (A) Effect of Solubrinal or BAPTA
on ER stress protein expression in DU-145 and PC-3 cells. Protein expression of ER-stress was examined in pre-treated with BAPTA or Salubrinal
in DU-145 and PC-3 cells, and western blot experiments were performed as described previously. (B) Inhibition of intracellular calcium or calpain
reveses shikonin induced inhibition of cell viability. Cell viability was quantified using the CCK-8 assay in BAPTA or Calpeptin pretreated DU-145
and PC-3 cells. Data is expressed in means ± SEM and represents the results of three independent experiments.
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(Figure 6B) or the ER stress inhibitor Salubrinal (Figure 6C)
significantly inhibited the Shikonin induced caspase activa-
tion in DU-145 and PC-3 prostate cancer cells. Further-
more, cell viability assays with pretreatment of either the
pan caspase inhibitor (Z-VAD-FMK) or the caspase-9 (Z-
LEHD-FMK)or caspase-3 inhibitor (Z-DEVD-FMK) con-
firmed a sequential activation of caspases upon Shikonin
treatment (Additional file 2: Figure S3). Further to define
the role of ROS-Calcium Stress mediated modulation of
mitochondrial membrane potential, we had pretreated
prostate cancer with ROS scavengers (NAC,GSH or
Catalase) and the calpain inhibitor calpeptin as described
in material methods. Our results suggested that both ROS
and intracellular calcium signaling are crucial for mito-
chondrial apoptosis in prostate cancer cells. Additionally
we also observed that either inhibition of caspase 9, 3 or
Salubrinal prevented Shikonin induced reduction of cell
viability (Figure 7A), and formation of apoptotic bodies in
these cells (Figure 7B) as a marker of apoptotic cell death.
Collectively these results indicated that ER stress playedan critical role in the shikonin induced apoptosis of pros-
tate cancer cells.
Discussion
Shikonin effectively induces apoptosis, necrosis and
necroptosis in cancer cells [10,14,23]. Shikonin is
known to selective killing of prostate cancer cell types,
while sparing normal cells [14]. However nothing was
known regarding the effects of Shikonin on regulation
of the ROS-Ca2+-pro apoptotic-ER stress in prostate
cancer cells. Using in vitro assays we report that the
natural naphthoquinone Shikonin induces cell death in
DU-145 and PC-3 prostate cancer cell lines through the
modulation of the ER stress and the mitochondrial
apoptotic pathway. Furthermore, for the first time showed
that Shikonin induces apoptosis in prostate cancer cells
through the ROS mediated-intracellular Ca2+-proapoptotic
ER stress associated mitochondrial dysfunction.
Previous studies have established that increase in the
intracellular Ca2+levels lead to the activation of ROS and
is considered as a second messenger in ER stress
A Shikonin                    +     + 



















































































































Figure 6 ER stress inhibition attenuates Shikonin induced mitochondrial apoptosis. (A) DU-145 and PC-3 cells were treated with either
Shikonin (2.5 μM) alone for 24 h or pretreated with ER stress inhibitor Salubrinal (10 μM) for 24 h and subsequently treated with Shikonin. Protein
expression was measured by western blotting as described in the Methods section. Shikonin treatment resulted in a marked reduction in the expression of
Bcl-2 and an increase in the levels of Bax and cleaved PARP when compared with the controls. Pretreatment with ER stress inhibitor Salubrinal led to the
increased expression of Bcl-2 and the decreased expression of Bax and cleaved PARP. (B) Pretreatment with caspase inhibitors reversed Shikonin induced
caspase activation. Treatment of cells with Shikonin (2.5 μM) for 24 h resulted in a marked reduction of shikonin induced caspase-9 and caspase-3 activities.
(C) Inhibition of ER suppressed shikonin induced casapase activity. Prostate cancer cells were pretreated with Salubrinal (10 μM), caspase 3 and 9 activity
were performed by colorimetric assay as described in material and method section. (D) ER stress regulates mitochondrial membrane potential in Shikonin
treated DU-145 and PC-3 cells. DU-145 and PC-3 cells were treated with either Shikonin (2.5 μΜ) alone or along with pretreatment with salubrinal (10 μM)
for 24 h, and then incubated with mitochondria specific dye JC-1 (10 m g/ml aft 37°C for 15 min), and the florescence was monitored using
fluorimeter (Excitation 530 nm/Fluorescence 590 nm) for measurement of the mitochondrial membrane potential. Shikonin treatment significantly
reduced mitochondrial membrane potential whereas pretreatment of ER stress inhibitor reversed this effect. Data is expressed in means ± SEM and
represents the results of three independent experiments.
Gara et al. Journal of Biomedical Science  (2015) 22:26 Page 9 of 12signaling [37]. In this study, treatment of DU-145 and
PC-3 cells with Shikonin resulted in marked increase in the
levels of intracellular Ca2+ within 60 min and ROS within
90 min. The majority of Ca2+ remains in the ER, but ER
stress leads to the release of Ca2+ [37]. Moreover, pretreat-
ment of cells with antioxidants like NAC, GSH or Catalase
markedly decreased the levels of intracellular Ca2+, suggest-
ing that intracellular ROS were directly involved in the
cytotoxic action of Shikonin (Figures 2 and 3). These data
indicated that Shikonin induces production of ROS
and activates ER stress and the subsequent release ofCa2+ in both DU-145 and PC-3 cells lead to cell death.
Our result is consistent with previous reports that ROS
activates ER dependent apoptosis in cancer cells [27-29].
Our results also indicated that the treatment of these cells
with Shikonin induceds ER stress leading to the elevation
in the levels of GRP78/Bip and CHOP/GADD153, and the
phosphorylation of PERK and eIF2α (Figure 4A), while
pretreatment with antioxidants attenuated these effects
(Figure 4B).
The members of the Bcl-2 family of proteins are im-
portant regulators of apoptotic cell death [38]. Although
Figure 7 Caspases and ER stress regulates Shikonin induced cell death in prostate cancer cells. (A) Shikonin regulated caspase dependent
cell death in DU-145 and PC-3 cells. Cells were preincubated with 50 μM of caspase-3 or 9 inhibitors, for 2 h, CCK-8 assay was performed after 48 h
post treatment of Shikonin in these cells. Data is expressed in means ± SEM and represent the results of three independent experiments
(p < 0.05). (B) Shikonin treatment induces apoptotic phenotype in prostate cancer cells. DU-145 and PC-3 cells were treated with 2.5 μM
for 24 h, and their nuclear morphology was examined using DAPI staining in with or without salubrinal pre-incubated prostate cancer
cells. In contrast to the control group, the group treated with Shikonin showed characteristic apoptotic phenotypes including heterogeneous staining,
chromatin condensation, and DNA fragmentation. However the group pretreated with Salubrinal significantly reversed the Shikonin induced effect in both
cell types. (C) The proposed shikonin induced cell death pathways in prostate cancer cells. Shikonin can directly influences intracellular calcium, and ER
stress and activated ROS dependent mitochondrial apoptosis. Alternatively, Shikonin induced ROS may regulated intracellular calcium, and ER stress and cell
death involving mitochondria and caspases in prostate cancer cells.
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cell death is clear, the mechanism by which they are reg-
ulated by ER stress is not well understood. Until re-
cently, Bcl-2 proteins were thought to regulate the
mitochondrial-mediated apoptotic pathway exclusively
[38,39]. One of the recent studies linked ER stress-
induced cell death to the Bcl-2 family of proteins
showed that overexpression of Bcl-2 or the deficiency of
Bax and Bak conferred protection against lethal ER
stress [38]. Stress signals are relayed from the ER to
mitochondria, and ER stress induced apoptosis, similar
to mitochondrial-mediated apoptosis regulated by the
Bcl-2 family of proteins [39]. The ratio of the Bax/Bcl-2
is critical for the induction of apoptosis [40]. ER stress
inducers including cellular stress inducers have also been
shown to induce a change in the conformation of Bax,resulting in its accumulation on the mitochondria, and
to induce the release of cytochrome c from the mito-
chondria into the cytosol [31,41,42]. Cytosolic cyto-
chrome c then binds to Apaf-1, leading to the activation
of caspase-3 and PARP protein [43]. The present results
also indicate that the reduced expression of antiapoptotic
Bcl-2 protein and the increased expression of the pro-
apoptotic Bax protein facilitated the Shikonin-mediated cell
death of these cells (Figure 6), which increases the ratio of
Bax/Bcl-2. This may be responsible for the concomitant
execution phase of apoptosis observed in these cells, which
included the disruption of the mitochondrial membrane
(Figure 6). As the level of cytochrome c increases in the
cytosol, it leads to the activation of the procaspase-9 and
caspase- 3 [44]. Activated caspase-3 is the key executioner
of apoptosis and the cleaved caspase-3 leads to the cleavage
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[45,46]. The present results revealed that the treatment
of prostate cancer cells with Shikonin led to the activa-
tion of caspase-9, caspase-3, and PARP (Figure 1).
Salubrinal was identified as a selective inhibitor of
phosphatases that act on eIF2α thereby maintaining
protein phosphorylation and offering protection from
the adverse effects of ER stress. Inhibition of ER stress
in DU-145 and PC-3 cells by salubrinal in the present
study led to the increased expression of Bcl-2 and
caspase-9, and caspase-3 activities and the decreased
expression of Bax (Figure 6B), caspase dependent cell
death (Figure 7A) and DNA damage as evident by the nu-
clear condensation indicated by DAPI staining (Figure 7B).
Natural compounds like shikonin might have multiple cel-
lular targets in order to achieve their biological beneficial
effects such as tumor growth inhibition [14,16]. A previous
study using prostate cancer cells had indicated that the
tumor proteasomal chymotrypsin subunit is one of the cel-
lular as well as in vivo biological targets of shikonin [46].
Our results are consistent with is study as it demonstrates
that shikonin with established proteasomal inhibitory activ-
ity induces apoptosis through induction of reactive oxygen
species and endoplasmic reticulum stress-in prostate cancer
cells [47] (Figure 7C).
Conclusion
Taken together our studies suggest that (i) Shikonin in-
hibits proliferation of hormone refractory prostate
cancer cells through the induction of ROS, mediated
activation of ER stress and intracellular Ca2+, and (ii)
induction of mitochondrial apoptotic pathway medi-
ated through the enhanced expression of Bax, disrup-
tion of the mitochondrial membrane potential, PARP
cleavage and activation of caspase-9 and caspase-3.
This ability of Shikonin to induce dual pathways of cell
death underscores its potential as a chemotherapeutic
agent against hormone refractory prostate cancers
need for further evaluation using in vivo models.
Additional files
Additional file 1: Table S1. Summary of cell lines used in this study.
Additional file 2: Figure S1. Shikonin treatment inhibits cell viabilities
of multiple cancer cells while sparing normal cell types. (A) Transformed
cells of diverse origin (Ishikawa: endometrial adenocarcinoma, C33A:
cervical cancer cells, LN229: human glioblastoma cancer cells and CAL 27:
oral adenosquamous cells) were treated with various doses of shikonin
(0.5,1, 2.5, 5 and 10 μM) for 24 h and the cell viabilities were assayed using
CCK-8 assay. (B) Nontransformed cells of diverse origin, i.e. oral keratinocytes;
human astrocytes; human mammary epithelial cells (HMEC); and peripheral
blood mononuclear cells (PBMCs) were treated with various doses of shikonin
(0.5,1, 2.5, 5 and 10 μM) for 24 h and cell viabilities were assayed using CCK-8
assay. Data is expressed in means ± SEM and represent the results of three
independent experiments (*p < 0.05). Figure S2. Shikonin treatment inhibits
cellular proliferation of prostate cancer cells while sparing normal prostateepithelial cells (PrECs). Normal prostate epithelial (PrEC) or prostate
cancer cells (DU-145 or PC-3) were treated with various doses of
shikonin (0.5,1, 2.5, 5 and 10 μM) for 24 h and the cell proliferation was
quantified through bromodeoxyuridine (BrdU) incorporation into DNA
using a nonradioactive colorimetric assay as described in the materials
and methods section. Data is expressed in means ± SEM and represent
the results of three independent experiments (*p < 0.05). Figure S3.
Inhibition of caspase activity (Pan caspase, caspase-9 and caspase-3
activities) reverses Shikonin induced inhibition of cell viability in
prostate cancer cells, indicating sequential activation of caspases.
Prostate cancer cells (DU-145 or PC-3) were preincubated with caspase
inhibitors (Pan caspase Inhibitor: Z-VAD-FMK, Caspase −9 Inhibitor:
Z-LEHD-FMK and Caspase −3 Inhibitor: Z-DEVD-FMK at a dose of
20 μM) alone or in combination for 2 h and subsequently treated with
Shikonin for 24 h. Subsequently, cell viabilities were assayed using
CCK-8 assay. Data is expressed in means ± SEM and represent the
results of three independent experiments (*p < 0.05).
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